Advaxis, Inc. (ADXS)

OTCMKTS: ADXS · Delayed Price · USD
2.16
-0.04 (-2.04%)
Sep 30, 2022 4:00 PM EDT - Market closed
-2.04%
Market Cap 3.92M
Revenue (ttm) 250,000
Net Income (ttm) -15.21M
Shares Out 1.82M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Jun 6, 2022
Volume 4,192
Open 2.00
Previous Close 2.21
Day's Range 2.00 - 2.30
52-Week Range 2.00 - 44.80
Beta 2.21
Analysts Buy
Price Target 2.30 (+6.5%)
Earnings Date Sep 16, 2022

About ADXS

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunothe... [Read more...]

Industry Biotechnology
Founded 2002
CEO Kenneth Berlin
Employees 14
Stock Exchange OTCMKTS
Ticker Symbol ADXS
Full Company Profile

Financial Performance

In 2021, Advaxis's revenue was $3.24 million, an increase of 1,180.63% compared to the previous year's $253,000. Losses were -$17.86 million, -32.52% less than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ADXS stock is "Buy." The 12-month stock price forecast is 2.3, which is an increase of 6.48% from the latest price.

Price Target
$2.3
(6.48% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update

Announced completion of first dose level and enrollment initiation for second dose level in investigator-sponsored study of ADXS-504 in biochemically recurrent prostate cancer

2 weeks ago - GlobeNewsWire

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

Evaluation completed of first dose level in investigator-sponsored study in biochemically recurrent prostate cancer

3 months ago - GlobeNewsWire

Advaxis Reports Second Quarter Ended April 30, 2022 Financial Results and Provides a Business Update

Announced Publication of ADXS-PSA Data in The Oncologist

3 months ago - GlobeNewsWire

Advaxis, Inc. Announces 1-for-80 Reverse Stock Split

MONMOUTH JUNCTION, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunot...

3 months ago - GlobeNewsWire

Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic No...

Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients with prior disease progression on KEYTRUDA ® (pemb...

4 months ago - GlobeNewsWire

Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

MONMOUTH JUNCTION, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products...

5 months ago - GlobeNewsWire

Advaxis Announces Publication of ADXS-PSA Data in The Oncologist

ADXS-PSA in combination with KEYTRUDA ® in metastatic castration-resistant prostate cancer (mCRPC) is associated with prolonged overall survival in this population, particularly in patients with viscera...

5 months ago - GlobeNewsWire

ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the...

NEW YORK--(BUSINESS WIRE)--Kahn Swick & Foti, LLC and Monteverde & Associates PC announce that, on March 28, 2022, Advaxis, Inc. issued a Supplemental Proxy Statement that includes additional clarifying...

6 months ago - Business Wire

Advaxis Reports First Quarter Ended January 31, 2022 Financial Results and Provides a Business Update

Presented Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones

6 months ago - GlobeNewsWire

Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update

MONMOUTH JUNCTION, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...

7 months ago - GlobeNewsWire

Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement

MONMOUTH JUNCTION, N.J., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...

8 months ago - GlobeNewsWire

Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones

Updated data show a second partial response in Part B

8 months ago - GlobeNewsWire

OTC Markets Group Welcomes Advaxis, Inc. to OTCQX

NEW YORK, Dec. 23, 2021 /PRNewswire/ --  OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for over 11,000 U.S. and global securities, today announced Advaxis, Inc. (OTCQX: ADXS), a cl...

9 months ago - PRNewsWire

Advaxis Announces Acceptance for Trading on the OTCQX

MONMOUTH JUNCTION, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...

9 months ago - GlobeNewsWire

Advaxis to Continue to Explore Additional Options to Maximize Stockholder Value

Stockholders approved Proposal 1 in support of Biosight merger

9 months ago - GlobeNewsWire

Advaxis Issues Letter to Stockholders Regarding Recent Special Meeting Results

Stockholders passed Proposals 1 (the Merger) and 4 (Executive Compensation)

9 months ago - GlobeNewsWire

Advaxis Issues Letter and Second Video Message to Stockholders Regarding Upcoming Special Meeting

Company releases video message highlighting the need for all proposals to pass in order to consummate the proposed Biosight transaction

10 months ago - GlobeNewsWire

Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Transaction with Biosight, Ltd. and...

MONMOUTH JUNCTION, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and commercializat...

10 months ago - GlobeNewsWire

Advaxis, Inc. Issues Letter to Stockholders

Advaxis urges stockholders to carefully evaluate the potential outcomes of the vote on the proposed merger with Biosight and vote FOR all proposals Advaxis urges stockholders to carefully evaluate the p...

10 months ago - GlobeNewsWire

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Advaxis Stockholders Vote “FOR” Propose...

Advaxis urges stockholders to vote “FOR” the merger with Biosight and all proposals Advaxis urges stockholders to vote “FOR” the merger with Biosight and all proposals

10 months ago - GlobeNewsWire

Biosight Encourages Advaxis Stockholders to Vote “FOR” Proposed Merger

Combined company, to be named Biosight Therapeutics, expected to be well-positioned to leverage its compelling oncology therapeutics pipeline, strong cash position, and accomplished management and Board...

10 months ago - GlobeNewsWire

Advaxis Issues Letter and Video Message to Stockholders Regarding Upcoming Special Meeting

Company releases video message highlighting strategic rationale and benefits of proposed Biosight transaction for Advaxis stockholders

10 months ago - GlobeNewsWire

Leading Independent Proxy Advisory Firm ISS Recommends Advaxis Stockholders Vote “FOR” the Merger with Biosight

MONMOUTH JUNCTION, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products...

10 months ago - GlobeNewsWire

6 of the Hottest Stocks to Pick Up for Less Than $1

These penny stocks are trading for under a dollar, but could change that in the coming months with their strong fundamentals. The post 6 of the Hottest Stocks to Pick Up for Less Than $1 appeared first ...

Other symbols: SRGA
11 months ago - InvestorPlace

Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results and Provides a Business Update

Entered definitive merger agreement with Biosight Ltd. to advance pipeline of clinical-stage oncology programs for solid tumors and hematological malignancies

1 year ago - GlobeNewsWire